Ezra's Notes Checked November 16, 2026
Investor Holdings

By @ezracrangle

← Seth Klarman, latest 13F

Seth Klarman · Q1 2018

Baupost Group

Portfolio at the end of Q1 2018, from the 13F filed May 14, 2018. See the filing on EDGAR ↗

CompanyWeightValueSharesPriceHeld sinceChange
Cheniere Energy LNG · history 10.7% $1.11B 20,726,340 $53.45 Q1 2014 No change
Synchrony SYF · history 9.5% $982.3M 29,295,030 $33.53 Q3 2016 No change
Twenty-First Century Fox FOXA · history 9.4% $975.5M 26,588,731 $36.69 Q3 2015 Add 19%
Viasat VSAT · history 8.7% $897.6M 13,658,137 $65.72 Q2 2013 or earlier Add 4%
Allergan AGN · history 7.7% $799.4M 4,750,000 $168.29 Q1 2016 Add 6%
Qorvo QRVO · history 7.5% $775.0M 11,000,000 $70.45 Q1 2017 No change
Time Warner TWX · history 7.4% $766.1M 8,100,000 $94.58 Q4 2017 No change
Pioneer Natural Resources PXD · history 6.6% $687.1M 4,000,000 $171.78 Q3 2017 Add 100%
Antero Resources AR · history 5.1% $527.8M 26,587,791 $19.85 Q3 2014 Add 8%
Twenty-First Century Fox FOX · history 4.0% $415.8M 11,433,358 $36.37 Q3 2015 Add 9%
Cardinal Health CAH · history 3.1% $319.7M 5,100,000 $62.68 Q4 2016 No change
Colony NorthStar CLNS · history 2.7% $279.2M 49,687,370 $5.62 Q1 2017 Add 4%
PBF Energy PBF · history 2.6% $268.6M 7,924,175 $33.90 Q3 2013 Reduce 27%
Atara Biotherapeutics ATRA · history 2.4% $243.9M 6,254,632 $39.00 Q4 2014 Add 17%
McKesson MCK · history 2.2% $227.6M 1,615,700 $140.87 Q3 2017 Add 19%
Theravance Biopharma TBPH · history 2.2% $225.7M 9,309,168 $24.25 Q2 2014 No change
Veritiv VRTV · history 1.4% $149.9M 3,824,385 $39.20 Q3 2014 Add 5%
PG&E PCG · history 1.3% $138.4M 3,149,972 $43.93 Q1 2018 Buy
Cencora COR · history 1.1% $113.6M 1,317,216 $86.21 Q3 2017 Reduce 8%
Keryx Biopharmaceuticals KERX · history 1.0% $105.5M 25,791,678 $4.09 Q1 2014 No change
AMC Entertainment AMC · history 0.7% $70.2M 5,000,000 $14.05 Q3 2017 No change
Novagold Resources NG · history 0.6% $58.3M 13,467,145 $4.33 Q2 2013 or earlier Add 25%
Tesla TSLA.CV · convertible notes · history 0.5% $52.2M 50,000,000 prn Q1 2018 Buy
GTY Technology GTYH.U · units · history 0.4% $45.5M 4,400,000 $10.35 Q4 2016 No change
Paratek Pharmaceuticals PRTK · history 0.3% $31.1M 2,394,498 $13.00 Q4 2014 No change
Theravance Biopharma TBPH.CV · convertible notes · history 0.3% $30.2M 30,000,000 prn Q4 2016 No change
Saban Capital Acquisition SCAC · history 0.2% $23.1M 2,326,500 $9.94 Q4 2016 No change
Sentinel Energy Services STNL.U · units · history 0.2% $15.9M 1,600,000 $9.92 Q4 2017 No change
ChipMOS IMOS · history 0.1% $14.8M 933,658 $15.85 Q2 2013 or earlier Reduce 37%
Trilogy Metals TMQ · history 0.1% $13.4M 10,600,758 $1.26 Q2 2013 or earlier No change
Forward Pharma FWP · history 0.1% $6.2M 2,848,003 $2.17 Q4 2014 Reduce 32%
Saban Capital Acquisition SCAC.WS · warrants · history 0.0% $1.5M 1,163,250 $1.30 Q4 2016 No change
Orexigen Therapeutics OREX · history 0.0% $465K 2,226,839 $0.21 Q3 2015 No change
33 positions100.0%$10.37B

Weight is the position's share of the total value in this 13F, not of the whole fund. Price is the value divided by the number of shares, so it's the price at the end of the quarter, as the firm reported it. Change compares share counts with Q4 2017, adjusted for stock splits.

Sector weighting

Sector weights in this 13F
Media & telecom30.1%
Energy25.0%
Health care20.3%
Financials & real estate12.6%
Technology8.1%
Industrials1.4%
Utilities1.3%
Materials0.7%
Consumer discretionary0.5%

What changed from Q4 2017

← Q4 2017 Q2 2018 →